Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Shanghai Changzheng Hospital |
---|---|
Information provided by: | Shanghai Changzheng Hospital |
ClinicalTrials.gov Identifier: | NCT00663182 |
The aim of this study is to evaluate the effect of Entecavir for patients With decompensated HBV-Related cirrhosis.
Condition | Intervention | Phase |
---|---|---|
Hepatitis B Virus Decompensated Cirrhosis |
Drug: Entecavir |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Placebo Control, Single Group Assignment, Efficacy Study |
Official Title: | Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial |
Estimated Enrollment: | 200 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | December 2012 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
Patients with decompensated HBV-related cirrhosis
|
Drug: Entecavir
Entecavir 0.5 mg/d
|
B: No Intervention
Untreated
|
Chronic hepatitis B is one of the most widespread viral infections worldwide, potentially leading to liver cirrhosis and hepatocellular carcinoma.
Previous studies demonstrated that patients with active viral replication, defined as the presence of detectable serum HBV-DNA or HBeAg, were at increased risk of developing progressive liver disease or death.The prognosis of decompensated cirrhosis resulting from chronic hepatitis B virus infection is poor. Anti-viral therapy in decompensated HBV-related cirrhosis has been recommended by the American Association for the Study of Liver Diseases. However, no high quality research on the effectiveness of anti-viral therapy in decompensated cirrhosis has been performed.
Entecavir is a new nucleotide analogue, which has been proved effective in suppressing viral replication and decreasing the necroinflammatory response, was recommended as a first-line medication in AASLD guideline. Our purpose was to evaluate the effect of Entecavir for patients With decompensated HBV-Related cirrhosis. The main outcomes were liver function, HBV-DNA, disease progression, hepatocellular carcinoma, Child-Pugh score and the survival.
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Shanghai Changzheng Hospital ( Jian Shi ) |
Study ID Numbers: | Entecavir-01 |
Study First Received: | April 21, 2008 |
Last Updated: | April 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00663182 History of Changes |
Health Authority: | China: Ministry of Health |
Entecavir cirrhosis anti-viral therapy |
Virus Diseases Hepatitis Liver Diseases Entecavir Digestive System Diseases Fibrosis |
Hepatitis B Hepatitis, Viral, Human DNA Virus Infections Liver Cirrhosis Antiviral Agents |
Anti-Infective Agents Liver Diseases Fibrosis Hepatitis, Viral, Human Liver Cirrhosis Hepadnaviridae Infections Antiviral Agents Pharmacologic Actions |
Hepatitis Virus Diseases Digestive System Diseases Pathologic Processes Entecavir Therapeutic Uses Hepatitis B DNA Virus Infections |